Chart of Day: SPDR S&P Biotech ETF (XBI) – 1/14

Keep an eye on biotech M&A.

Over the last few days, Merck said it would pay $680 million for Harpoon Therapeutics. Johnson & Johnson also said it would buy Ambrx Biopharma for $2 billion. Both come just weeks after Bristol Myers bought Karuna Therapeutics for $14 billion, and RayzeBio for $4.1 billion. Even AbbVie just bought ImmunoGen for $10.1 billion, and Cerevel Therapeutics for $8.7 billion.

However, this may just be the start of a bigger M&A trend.

In fact, 2024 will likely see a series of new, and significant, merger and acquisition (M&A) deals for biopharma, building on a flurry of buyout announcements seen in the closing weeks of 2023, according to a report released to coincide with the 42nd Annual J.P. Morgan Healthcare Conference,” as reported by Genetic Engineering & Biotechnology News.

One way to trade the excitement is with an ETF, such as the SPDR S&P Biotech ETF (XBI).


With an expense ratio of 0.35%, the ETF offers exposure to the S&P Biotechnology Select Industry Index. Some of its top holdings include Biogen, Veracyte, Moderna, Gilead Sciences, Amgen, and VIR Biotechnology to name a few. The ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.